---
title: "Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis"
description: "Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects"
url: "https://www.clareohealth.com/clinical-trials/NCT02462967"
---

Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also have a liver biopsy with cirrhosis (Ishak stage 5 or 6), presumably due to NASH, excluding subjects with medium and large varices and those with decompensated cirrhosis. Subjects with portal hypertension and cirrhosis will be randomly assigned (1:1:1 ratio) to receive 1 of 3 treatment assignments including placebo, GR MD 02 in a dose of 2 mg/kg lean body mass, or GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 intravenous infusions. The primary endpoint analysis is the baseline adjusted change in HVPG at 1 year (53 55 weeks) in subjects treated with placebo as compared to subjects treated with GR MD 02 (2 mg/kg/week or 8 mg/kg/week). An esophagogastroduodenoscopy (EGD) with evaluation for varices, HVPG, and liver biopsy will be performed before the first infusion and after the final 26th dose of the investigational medicinal product (IMP). Additionally, subjects will undergo a FibroScan (if available) prior to the first infusion, at Infusion Visit 13, and 14 to 28 days following final 26th infusion, an methacetin breath test (MBT), will be performed if available at screening, at Infusion Visit 13, and 14 to 28 days after the final infusion, and blood will be collected for assessment of biomarkers. All subjects are to attend 2 postdose visits: the first will occur 14 to 28 days after the final dose administration and a second will occur 14 days following the first postdose visit. Subjects will be offered enrollment into a subsequent separate study, an open label extension study, if there is adequate tolerability and no safety issues or signs of clinical progression that would recommend discontinuation. Subjects who do not enroll in the open label extension study will be contacted via telephone every 6 months for 2 years and annually thereafter for a total of 4 years.

## Key Facts

**ID:** NCT02462967
**Status:** COMPLETED
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 162
**Sponsor:** Galectin Therapeutics Inc.

## About This Study

This clinical trial is testing GR-MD-02, a new treatment, for patients with liver fibrosis and portal hypertension caused by NASH cirrhosis. It aims to see if this treatment can improve liver health compared to a placebo (a fake treatment).

## Conditions

- Hypertension, Portal

## Interventions

**DRUG: GR-MD-02**
GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3

**DRUG: Placebo**
Placebo for GR-MD-02

## Eligibility

Inclusion Criteria: 1. Has a HVPG measurement ≥6 mm Hg. 2.

## Who Can Participate

**Minimum age:** 18

**Maximum age:** 75

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Cedars Sinai Medical Center, Los Angeles, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- University of California San Diego Medical Center, San Diego, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- Florida Digestive Health Specialist, Lakewood Rch, Florida, United States
- University of Miami, Miami, Florida, United States
- IMIC, Palmetto Bay, Florida, United States
- Tampa General Medical Group, Tampa, Florida, United States
- Piedmont Hospital, Atlanta, Georgia, United States
- Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- Tulane University Health Sciences Center, New Orleans, Louisiana, United States
- Mercy Medical Center, Baltimore, Maryland, United States
- Walter Reed National Military Medical Center, Bethesda, Maryland, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Minnesota Gastroenterology PA, Saint Paul, Minnesota, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Kansas City VA Medical Center, Kansas City, Missouri, United States
- Saint Louis University, St Louis, Missouri, United States
- North Shore University Hospital, Manhasset, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Digestive Health Specialists, Winston-Salem, North Carolina, United States
- University Hospitals Case Medical Center, Cleveland, Ohio, United States
- Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- University Gastroenterology, Providence, Rhode Island, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Texas Clinical Research Institute LLC, Arlington, Texas, United States
- Texas Digestive Research Center, Dallas, Texas, United States
- San Antonio Military Medical Center, Fort Sam Houston, Texas, United States
- St Luke's Episcopal Hospital, Houston, Texas, United States
- Pinnacle Clinical Research, PLLC, Live Oak, Texas, United States
- Texas Liver Institute, San Antonio, Texas, United States
- Intermountain Medical Center, Murray, Utah, United States
- Mary Immaculate Hospital, Newport News, Virginia, United States
- Digestive and Liver Disease Specialists, Norfolk, Virginia, United States
- Bon Secours St. Mary's Hospital of Richmond, Richmond, Virginia, United States
- Mcguire Veterans Affairs Medical Center, Richmond, Virginia, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- Swedish Medical Center, Seattle, Washington, United States
- University of Washington, Seattle, Washington, United States

## Contact Information

## Important Dates

**Study start:** June 1, 2015

**Completion date:** October 1, 2017

**Last updated:** October 8, 2020

## Collaborators

- Dr. Naga Chalasani, MD, Indiana University
- Dr. Stephen A. Harrison, MD, Brooke Army Medical Center

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have portal hypertension with a measurement of 6 mm Hg or higher.
- Your liver biopsy shows cirrhosis due to NASH.
- You are between 18 and 75 years old and willing to participate in a clinical trial.
- You have not had any major liver complications like variceal bleeding.

### Questions to Ask

- What are the potential benefits and risks of participating in this trial?
- How does GR-MD-02 compare to my current treatment options?
- What tests will I need to undergo during the trial?
- How often will I need to visit the clinic for treatment?
- What happens if I experience side effects?
- Will I have access to additional support or follow-up after the trial?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02462967)
